Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sep 28, 2010

Premium

OncoMethylome Sciences this week appointed Melissa Thompson as vice president of regulatory affairs and quality assurance, and Christopher Thibodeau as vice president of commercial operations.

Thompson has provided consultative services to a number of pharmaceutical and biotech companies in the past, including Affymetrix, Signature Genomics, and Exonhit Therapeutics.

Thibodeau joins OncoMethylome from Agendia, where he was senior director of marketing. He held similar positions at Numira Biosciences, US Labs, and Ventana Medical.


Huron Technologies, a Waterloo, Canada-based digital pathology and microarray tools company, recently announced a new management team after Confocal acquired a controlling interest in the firm.

Savvas Chamberlain has been named acting CEO. Chamberlain founded imaging firm Dalsa in 1980 and served as its CEO until 2007. He now is chairman of its board. In addition to Chamberlain's appointment, Mike Panayi has been named chief financial officer; Audil Virk has been appointed chief operating officer; Savvas Damaskinos is now chief technology officer; and Ted Dixon has been appointed vice president of science and technology.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.